ABcann Global Stock (TSXV: ABCN) (OTC: ABCCF) - Investor Dashboard
|License Renewal Month:||October 2017|
|Licensed Capacity:||625 kilograms|
|Number of Patients:||na|
Financials (pro forma 09/30)
|Cash on hand:||$28.9mm|
|Revenues – Last Quarter:||N/A|
|Adj. Gross Margin :||N/A|
Capital Structure (04/23/17)
|Last Financing:||12.875mm shares at $0.80|
Licensed since March 2014, ABcann sets itself apart from other Canadian licensed producers with its 94% customer retention rate, its focus on organic cultivation in proprietary growing chambers and its industry-leading production yields in excess of 250 grams per sq. ft., double the industry average. The company, which is in the process of developing its 65-acre site with a second 150K sq. ft. facility, has a research partnership with the University of Guelph and and has supplied innovative cannabis inhaler device maker Syqe Medical with its standardized cannabis.
ABcann Global is expected to begin trading publicly within the next few days with the symbol ABCN on the TSX Venture. New Cannabis Ventures Managing Partner Alan Brochstein hosted ABcann CEO Aaron Keay, who discussed the company as he reviewed its corporate presentation and then took questions.
- Focus on pharmaceutical grade plant standardization
- 94.7% customer retention rate
- Organic production using exclusive, computer-controlled environmental system
- Expand existing facility and construct 2nd facility targeting 40 kg/annum production capacity
- Pursue global initiatives in Europe, Israel and Australia
- Active discussions to license production to U.S. operators
- Production through computer-controlled environmental systems
- Industry-leading efficiency in terms of yield per square foot
- Research partnership with University of Guelph
Above Industry Average Yields
ABcann’s standardized organic growing methods yield not only a higher quality product as reflected by its premium pricing but also a lower overall cost. According to PI Financial, ABcann is able to produce almost double the industry average as measured by grams per square foot.
Strong Advisory Board Led by
the “Father of Cannabis Medicine”
Dr. Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.
Institutional Analyst Coverage
JASON ZANDBERG, CFA
Curated Stories & News
New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. ABcann Global, Inc. is a client of NCV Media, LLC. Read our full disclaimer.